YOKNEAM, Israel, Sept. 26, 2016 (GLOBE NEWSWIRE)
-- Lumenis Ltd., the world's largest energy-based medical
device company for surgical, aesthetic and ophthalmic applications,
announced it will be the first laser company to participate in the
European Burn Association's Educational course on 'Post Burn
Reconstruction' at the 17th European Burn Association (EBA)
Congress, being held in Birmingham, U.K. from September 26-27,
2016.
"In the past decade and a half, there have been
major strides in the management of severe scars, especially with
the increased adoption of laser therapy approaches," said Gerd
Gauglitz, M.D., dermatologist at the Department of Dermatology and
Allergology, Ludwig Maximilians University, Munich, Germany. "Laser
scar therapy, particularly the Lumenis UltraPulse(TM) SCAAR FX(TM)
fractional CO2 ablative laser, has proven to be a significant
advancement in scar treatment and management and has been
progressively embraced as a promising tool in the multidisciplinary
treatment of complex burns and traumatic scars."
EBA attendees are invited to attend the
educational symposium featuring Dr. Gauglitz, who will share his
experience of burn scar treatments with UltraPulse SCAAR FX and
conduct live demonstrations of the procedure with two burn scar
patients:
Educational Symposium with
Live Demos
26 September, 08:40 - 10:10
"Ablative fractional laser for the improvement of hypertrophic burn
scars with UltraPulse"
Dr. Gerd Gauglitz
Since its introduction, the UltraPulse platform
has improved the quality of care and life for scar patients all
over the world. The innovative UltraPulse SCAAR FX technology is
becoming the standard of care for severe scar patients around the
world and has been used in many humanitarian missions, to treat
wounded warriors and war survivors. The technology is also being
used to treat Kim Phuc, a survivor of the Vietnam War bombing, also
recognized as "The Girl in the Picture."
"We are proud to be the first energy-based
technology company to participate in the European Burn Association
Congress Educational Course," said Tzipi Ozer-Armon, CEO of
Lumenis. "It is an honor to partner and collaborate with the
organization to help educate dermatologists about the latest
treatment advancements and to develop technology to further enhance
the care for burn patients everywhere."
At EBA, Lumenis will offer conference participants
the opportunity to register to win a preceptorship, featuring a
full day of hands-on training with the UltraPulse SCAAR FX from
leading industry experts in Europe. For more information about the
preceptorship opportunity, please
visithttp://information.lumenis.com/eba-course-ultrapulse-with-scaarfx.
For more about the Lumenis' family of fractional
ablative laser resurfacing products and its portfolio of innovative
scar treatment solutions, please visit the Lumenis booth #15 at the
conference.
About Lumenis
Lumenis is a global leader in the field of
minimally-invasive clinical solutions for the Surgical,
Ophthalmology and Aesthetic markets, and is a world-renowned expert
in developing and commercializing innovative energy-based
technologies, including Laser, Intense Pulsed Light (IPL) and
Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking
products have redefined medical treatments and have set numerous
technological and clinical gold-standards. Lumenis has
successfully created solutions for previously untreatable
conditions, as well as designed advanced technologies that have
revolutionized existing treatment methods. For more information
visit: www.lumenis.com.
Forward-Looking
Statements
Information provided in this press release may contain statements
relating to current expectations, estimates, forecasts and
projections about future events that are "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995. These forward-looking statements may include but are
not limited to the Company's plans, objectives and expectations for
future operations, including its projected results of operations.
Forward-looking statements are often characterized by the use of
forward-looking terminology such as "may," "will," "expect,"
"anticipate," "estimate," "continue," "believe," "should,"
"intend," "plan," "project" or other similar words, but are not the
only way these statements are identified. These forward-looking
statements are based upon our management's current estimates and
projections of future results or trends. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties, including those risks discussed under the heading
"Risk Factors" in our most recent Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission. These
forward-looking statements are made only as of the date hereof, and
the Company undertakes no obligation to update or revise the
forward-looking statements, whether as a result of new information,
future events or otherwise.